More work needed to crack the nut.

Abstract

The STOP II study provides high-quality evidence on the efficacy, safety and impact on quality of life of oral immunotherapy (OIT) in peanut-allergic children. Although the results are promising, significant concerns and knowledge gaps remain regarding the safety of OIT, its ability to induce long-term tolerance once regular peanut intake is stopped and, accordingly, long-term adherence. Peanut OIT therefore needs to be restricted to research studies aiming to complete the current evidence gaps.